Compare Stocks

Acusphere, Inc. operates as a specialty pharmaceutical company that develops and commercializes cardiovascular drugs. It offers Imagify (perflubutane polymer microspheres), a cardiovascular drug that evaluates myocardial perfusion and detects coronary artery disease. It provides Imagify as an injectable suspension. The company was formerly known as Polymers For Medicine, Inc. and changed its name to Acusphere, Inc. in March 2004. Acusphere, Inc. was founded in 1993 and is based in Watertown, Massachusetts.

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

AtheroNova, Inc. operates as biotechnology company. The company engages in the research and development, marketing, and sale of pharmaceutical preparations and pharmaceutical intellectual property. It develops intellectual property that uses certain pharmacological compounds for the treatment of atherosclerosis, which is the primary cause of various cardiovascular diseases. The company was founded by Giorgio Zadini and Filiberto Zadini in 1997 and is headquartered in Irvine, CA.

ARYx Therapeutics, Inc. discovers and develops novel therapies for large, chronic, and oral markets. The company uses its RetroMetabolic Drug Design technology to design structurally unique molecules that retain the efficacy of original drugs. Its products in clinical development portfolio include Tecarfarin (ATI-5923), an oral anticoagulant, which is in Phase III clinical development for the treatment of patients who are at risk for the formation of dangerous blood clots; and Budiodarone (ATI-2042), an oral antiarrhythmic agent that is in Phase IIb clinical development for the treatment of atrial fibrillation, a form of irregular heartbeat. The company's other clinical development products comprise ATI-7505, an oral prokinetic agent, which is in Phase IIb clinical development for the treatment of chronic constipation, gastroparesis, functional dyspepsia, irritable bowel syndrome with constipation, and gastroesophageal reflux disease; and ATI-9242, an antipsychotic agent in Phase I clinical development for the treatment of schizophrenia and other psychiatric disorders. It also focuses on ATI-20,000 for metabolic disorders and ATI-24,000 for gastrointestinal disorders that are in discovery stage. ARYx Therapeutics, Inc. was founded in 1997 and is based in Fremont, California.

Diadexus, Inc., a diagnostics company, focuses on the development and commercialization of cardiovascular diagnostic products addressing needs in cardiovascular disease. Its products include PLAC ELISA Test and the PLAC Activity Test that are designed to provide information on traditional risk factors, such as cholesterol levels to help identify individuals at risk of suffering a heart attack or stroke. The company's PLAC ELISA Test is an aid in predicting risk for coronary heart disease (CHD) and ischemic strokes associated with atherosclerosis; and PLAC Test for Lp-PLA2 (lipoprotein-associated phospholipase A2) Activity is used in conjunction with clinical evaluation and patient risk assessment as an aid in predicting risk of CHD in patients with no prior history of cardiovascular events. Its pipeline of proprietary biomarkers comprises proADM, proET-1, and proANP for the treatment of heart failure. The company markets its products to various national and regional clinical reference laboratories and hospitals in the United States, Europe, and internationally. The company is based in Poway, California. On June 13, 2016, Diadexus, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Northern District of California.